PMID- 32494195
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy 
      in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution 
      Experience in China.
PG  - 3323-3329
LID - 10.2147/CMAR.S248392 [doi]
AB  - OBJECTIVE: To investigate the curative and adverse effects (AEs) of additional 
      use of nimotuzumab combined with induction chemotherapy and concurrent 
      chemoradiotherapy in unresectable locoregionally advanced hypopharyngeal 
      carcinoma. PATIENTS AND METHODS: We retrospectively evaluated 36 patients with 
      stage III or IVA hypopharyngeal carcinoma who received induction chemotherapy 
      followed by concurrent chemoradiotherapy with or without nimotuzumab. The 
      induction chemotherapy included two or three cycles of TPF regimen. The 
      intensity-modulated radiation therapy (IMRT) dose was 70 Gy to the planning 
      target volume. Concurrent with radiotherapy, patients received chemotherapy 
      consisting of cisplatin q3w. Adjuvant chemotherapy consisting of TPF regimen was 
      administered 1 month later after concurrent chemoradiotherapy. Nimotuzumab (200 
      mg day 1, q3w) was given to patients concurrently with induction chemotherapy and 
      was administered concurrently with IMRT at a weekly dose of 200 mg. RESULTS: 
      After induction chemotherapy, the objective response rate in patients treated 
      with nimotuzumab (group A) versus those treated without nimotuzumab (group B) was 
      91.7% versus 58.3% (p=0.029). After concurrent chemoradiotherapy, the objective 
      response rate was 95.8% in group A versus 83.3% in group B (p=0.253). The median 
      follow-up was 22.6 months (range 8.9-39.5 months). The 2-year OS rate in group A 
      and group B were 62.5% (95% CI 55-70%) and 51.8% (95% CI 45-59%), respectively, 
      the 2-year OS rate in group A was better than group B, P<0.05. PFS was 23 months 
      (95% CI 19-27) in group A versus 18 months (95% CI 12-22) in group B, PFS was 
      longer in group A than group B, P<0.05. There was no significant difference in 
      AEs between the two groups. CONCLUSION: Additional use of nimotuzumab combined 
      with induction chemotherapy and concurrent chemoradiotherapy in unresectable 
      locoregionally advanced hypopharyngeal carcinoma yielded better short-term 
      efficacy, also may improve overall survival and progression-free survival than 
      patients without using nimotuzumab. The toxicity was tolerable.
CI  - (c) 2020 Tian et al.
FAU - Tian, Xin
AU  - Tian X
AD  - Department of Clinical Oncology, Shengjing Hospital of China Medical University, 
      Shenyang, Liaoning 110004, People's Republic of China.
FAU - Xuan, Ying
AU  - Xuan Y
AD  - Department of Clinical Oncology, Shengjing Hospital of China Medical University, 
      Shenyang, Liaoning 110004, People's Republic of China.
FAU - Wu, Rong
AU  - Wu R
AD  - Department of Clinical Oncology, Shengjing Hospital of China Medical University, 
      Shenyang, Liaoning 110004, People's Republic of China.
FAU - Gao, Song
AU  - Gao S
AD  - Department of Clinical Oncology, Shengjing Hospital of China Medical University, 
      Shenyang, Liaoning 110004, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200511
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7227783
OTO - NOTNLM
OT  - chemoradiotherapy
OT  - hypopharyngeal carcinoma
OT  - induction chemotherapy
OT  - locoregionally advanced
OT  - nimotuzumab
OT  - unresectable
COIS- The authors of this study declare no conflicts of interest.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
PMCR- 2020/05/11
CRDT- 2020/06/05 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/04/21 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/05/11 00:00 [pmc-release]
AID - 248392 [pii]
AID - 10.2147/CMAR.S248392 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 May 11;12:3323-3329. doi: 10.2147/CMAR.S248392. 
      eCollection 2020.